Integra LifeSciences Holdings Corporation (NASDAQ:IART) Receives $15.00 Consensus Price Target from Analysts

Shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) have earned a consensus recommendation of “Reduce” from the seven ratings firms that are covering the firm, MarketBeat Ratings reports. Three analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation and two have assigned a buy recommendation to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $15.00.

Several equities research analysts recently commented on IART shares. Wall Street Zen raised shares of Integra LifeSciences from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. JPMorgan Chase & Co. boosted their target price on shares of Integra LifeSciences from $12.00 to $13.00 and gave the stock an “underweight” rating in a research note on Friday, October 31st. Truist Financial restated a “hold” rating and set a $13.00 price target (down previously from $15.00) on shares of Integra LifeSciences in a research report on Monday, November 3rd. Weiss Ratings reiterated a “sell (e+)” rating on shares of Integra LifeSciences in a report on Monday, December 29th. Finally, Citigroup cut their price objective on Integra LifeSciences from $12.00 to $11.00 and set a “sell” rating for the company in a research note on Friday, October 31st.

Integra LifeSciences Price Performance

NASDAQ:IART opened at $11.18 on Thursday. The company has a quick ratio of 1.80, a current ratio of 3.14 and a debt-to-equity ratio of 1.73. Integra LifeSciences has a 52 week low of $10.60 and a 52 week high of $25.50. The stock’s 50-day moving average price is $12.37 and its 200-day moving average price is $13.29. The stock has a market capitalization of $870.83 million, a PE ratio of -1.73 and a beta of 1.04.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Global Retirement Partners LLC purchased a new stake in shares of Integra LifeSciences during the fourth quarter worth $25,000. GAMMA Investing LLC boosted its position in Integra LifeSciences by 55.3% during the third quarter. GAMMA Investing LLC now owns 2,565 shares of the life sciences company’s stock worth $37,000 after acquiring an additional 913 shares during the last quarter. Caitong International Asset Management Co. Ltd grew its stake in Integra LifeSciences by 205.9% during the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 3,132 shares of the life sciences company’s stock valued at $38,000 after acquiring an additional 2,108 shares in the last quarter. Osaic Holdings Inc. raised its holdings in Integra LifeSciences by 36.6% in the 2nd quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company’s stock valued at $51,000 after acquiring an additional 1,104 shares during the last quarter. Finally, AlphaQuest LLC acquired a new stake in Integra LifeSciences in the 2nd quarter valued at about $73,000. Hedge funds and other institutional investors own 84.78% of the company’s stock.

Integra LifeSciences Company Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.